| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma (NCT05626829) | Jian Guan | 2022-07-20 |
| PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05340270) | Guangxi Medical University | 2022-07-15 |
| Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening (NCT05447169) | Sun Yat-sen University | 2022-07-10 |
| A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC (NCT05433597) | Sun Yat-sen University | 2022-07-01 |
| Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study (NCT05417139) | Sun Yat-sen University | 2022-07-01 |
| Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma (NCT05211232) | Sun Yat-sen University | 2022-06-10 |
| Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma (NCT06189482) | Zeng Changhao | 2022-06-01 |
| Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma (NCT05352321) | Sun Yat-sen University | 2022-06-01 |
| Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma (NCT06248840) | Zeng Changhao | 2022-06-01 |
| Umbrella Biomarker-Guided Therapy in NPC (NCT04605562) | Sun Yat-sen University | 2022-06-01 |
| Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NCT05389306) | Sun Yat-sen University | 2022-05-25 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma (NCT05576272) | Qilu Pharmaceutical Co., Ltd. | 2022-05-19 |
| Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma (NCT05201859) | Sun Yat-sen University | 2022-05-17 |
| Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain (NCT05304468) | Sun Yat-sen University | 2022-05-11 |
| Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention (NCT05834712) | Sun Yat-sen University | 2022-05-11 |
| PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05341193) | Sun Yat-sen University | 2022-04-30 |
| Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma (NCT05508347) | Sichuan Cancer Hospital and Research Institute | 2022-04-20 |
| Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792) | Sun Yat-sen University | 2022-04-17 |
| Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma (NCT05097209) | Wei Jiang | 2022-04-06 |
| Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial (NCT05340491) | Sun Yat-sen University | 2022-04-01 |
| Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma (NCT05292027) | Sichuan Cancer Hospital and Research Institute | 2022-03-26 |
| Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (NCT04825990) | Gruppo Oncologico del Nord-Ovest | 2022-03-24 |
| PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (NCT05229315) | XIANG YANQUN | 2022-03-12 |
| Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma (NCT05147844) | Xinqiao Hospital of Chongqing | 2022-03-01 |
| Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05193617) | Sun Yat-sen University | 2022-01-20 |
| EBV CAR-T Cells for Nasopharyngeal Carcinoma (NCT05654077) | The Affiliated Hospital of Xuzhou Medical University | 2022-01-18 |
| Ovarian Function of Nasopharyngeal Carcinoma Women Survivors (NCT05183724) | Sun Yat-sen University | 2022-01-10 |
| Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy (NCT05674305) | Fudan University | 2022-01-01 |
| Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy (NCT05772208) | Fudan University | 2022-01-01 |
| 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma (NCT04813705) | Taizhou Hospital | 2022-01-01 |
| Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma (NCT05146050) | Sun Yat-sen University | 2021-12-08 |
| Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images (NCT05202626) | Chinese Academy of Sciences | 2021-12-01 |
| Immune Score Based Radiomics in Nasopharyngeal Carcinoma (NCT05126160) | Zhejiang Cancer Hospital | 2021-11-05 |
| Asian Multicenter Prospective Study of ctDNA Sequencing (NCT05099978) | National Cancer Center, Japan | 2021-11-01 |
| Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) (NCT04996758) | Sun Yat-sen University | 2021-10-30 |
| Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma (NCT05092217) | Eye & ENT Hospital of Fudan University | 2021-10-20 |
| Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC (NCT05166577) | Viracta Therapeutics, Inc. | 2021-10-08 |
| Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma (NCT05448885) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-09-01 |
| SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05020925) | Jiangsu HengRui Medicine Co., Ltd. | 2021-09-01 |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04974398) | Akeso | 2021-08-16 |
| Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition (NCT04436965) | Sun Yat-sen University | 2021-08-16 |
| Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04955886) | Fujian Cancer Hospital | 2021-08-01 |
| Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients (NCT06442709) | Affiliated Hospital of Nantong University | 2021-08-01 |
| PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma (NCT04907370) | Sun Yat-sen University | 2021-08-01 |
| Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements (NCT05037357) | Sun Yat-sen University | 2021-08-01 |
| Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma (NCT05177237) | Jiangxi Provincial Cancer Hospital | 2021-07-28 |
| Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy (NCT04978012) | Fudan University | 2021-07-25 |
| Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma (NCT04823468) | Jinsheng Hong | 2021-07-19 |
| An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC (NCT04890522) | Sun Yat-sen University | 2021-07-01 |
| The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04917770) | West China Hospital | 2021-06-30 |
| A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma (NCT04895345) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-15 |
| The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma (NCT04303975) | Jiarong Chen, MD | 2021-06-01 |
| Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma (NCT04944914) | Sun Yat-sen University | 2021-06-01 |
| The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC (NCT04929080) | Shanghai Junshi Bioscience Co., Ltd. | 2021-05-11 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Nedaplatin in Treatment for Nasopharyngeal Carcinoma (NCT04834206) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2021-05-01 |
| Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC (NCT04745741) | Fujian Cancer Hospital | 2021-05-01 |
| Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study (NCT05008471) | Sun Yat-sen University | 2021-04-26 |
| Magnifying NBI for Occult NPC (NCT04593186) | Chinese University of Hong Kong | 2021-04-15 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma (NCT04778956) | Sun Yat-sen University | 2021-03-03 |
| The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma (NCT04769076) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2021-03-01 |
| Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma (NCT04766359) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2021-03-01 |
| The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC (NCT04830267) | Chongqing University Cancer Hospital | 2021-03-01 |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (NCT04736810) | Akeso | 2021-02-25 |
| Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma (NCT04143984) | Shanghai Proton and Heavy Ion Center | 2021-01-19 |
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT04350190) | Wei Jiang | 2021-01-14 |
| Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma (NCT05232552) | Zhejiang Cancer Hospital | 2021-01-01 |
| Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC (NCT04557020) | Jiangxi Provincial Cancer Hospital | 2020-12-30 |
| Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients (NCT04292990) | Jiarong Chen, MD | 2020-12-01 |
| Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NCT04636632) | Sun Yat-sen University | 2020-11-24 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation (NCT04534855) | Sun Yat-sen University | 2020-09-01 |
| Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT04548271) | Sun Yat-sen University | 2020-09-01 |
| Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT04547088) | Sun Yat-sen University | 2020-09-01 |
| Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma (NCT04448522) | Sun Yat-sen University | 2020-08-18 |
| Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma (NCT04456322) | Sun Yat-sen University | 2020-08-17 |
| Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma (NCT04453813) | Sun Yat-sen University | 2020-07-03 |
| Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial (NCT04992988) | Cancer Hospital of Guangxi Medical University | 2020-06-28 |
| uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma (NCT04394065) | Sun Yat-sen University | 2020-06-20 |
| Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC (NCT04421469) | Fujian Cancer Hospital | 2020-06-15 |
| Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma (NCT04227509) | Seoul National University Hospital | 2020-06-04 |
| SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma (NCT04351282) | Fudan University | 2020-06-01 |
| EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) (NCT04072107) | Sun Yat-sen University | 2020-06-01 |
| To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC (NCT04387266) | Fujian Cancer Hospital | 2020-06-01 |
| Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma (NCT04447612) | The University of Hong Kong | 2020-06-01 |
| To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer (NCT04419324) | Chinese University of Hong Kong | 2020-06-01 |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. (NCT04405622) | Sun Yat-sen University | 2020-05-30 |
| Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients (NCT04394091) | Sun Yat-sen University | 2020-05-20 |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure (NCT04586088) | Sun Yat-sen University | 2020-05-05 |
| A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma (NCT04220307) | Akeso | 2020-04-26 |
| Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City (NCT04085900) | Zhongshan People's Hospital, Guangdong, China | 2020-04-01 |
| Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC (NCT04544969) | Sun Yat-sen University | 2020-04-01 |
| SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT04282070) | Jiangsu HengRui Medicine Co., Ltd. | 2020-03-27 |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma (NCT03984357) | Sun Yat-sen University | 2020-03-16 |
| Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC (NCT04396886) | The University of Hong Kong | 2020-02-27 |
| Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma (NCT04223024) | Sun Yat-sen University | 2020-01-31 |
| Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma (NCT04221516) | Nanfang Hospital, Southern Medical University | 2020-01-01 |
| Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma (NCT04136886) | Sun Yat-sen University | 2020-01-01 |
| Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients (NCT03925090) | Sun Yat-sen University | 2019-12-08 |